Veracyte VCYT 深 沪
等待开盘 12-20 09:30:00 美东时间
42.68
+0.640
+1.52%
华盛通- 最 高42.73
- 今 开41.47
- 成交量 27.69万股
- 最 低 41.32
- 昨 收 42.04
- 总市值 33.58亿
- 52周最高 50.71
- 市盈率 静 138.21
- 换手率 0.35%
- 52周最低 22.61
- 委 比 -2.56%
- 总股本 7867.16万
- 历史最高 86.03
- 量 比 0.60
- 振 幅 3.35%
- 历史最低 4.21
- 每 手 1
- 风险率 6.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Meihua International Medical Technologies, Fly-E Group And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around...
12-08 21:03
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Morgan Stanley Maintains Underweight on Veracyte, Raises Price Target to $48
Morgan Stanley analyst Tejas Savant maintains Veracyte (NASDAQ:VCYT) with a Underweight and raises the price target from $40 to $48.
12-03 02:02
Cathie Wood Bets Big On This Peter Thiel-Backed Coinbase Rival As Bitcoin Crashes Below $91,000
On Monday, Cathie Wood-led Ark Invest executed significant trades involving Bullish (NYSE:BLSH), Reddit Inc.
11-18 10:42
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
美股牛股 | Solid Power飙升超51%！与宝马及三星SDI合作推进全固态电池技术商业化；Lemonade涨超34%
Solid Power飙升超51%！与宝马及三星SDI合作推进全固态电池技术商业化；Lemonade涨超34%，Q3业绩大幅超预期并上调业绩指引>>
11-06 15:10
美股大行评级 | 最高325美元！10家机构集体上调AMD目标价；Pinterest遭14家大行下调目标价；大行对优步目标价分歧大，5家下调5家上调
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从3美元升至9美元；HC Wainwright & Co.：上调CervoMed评级至"买入"，目标价从11美元升至25美元
11-06 09:55
Johnson Controls, Babcock & Wilcox, Lemonade, Lumentum, Teva Pharmaceutical And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Nasdaq Composite gaining more than 200 points...
11-06 00:56
Needham Maintains Buy on Veracyte, Raises Price Target to $44
Needham analyst Mike Matson maintains Veracyte (NASDAQ:VCYT) with a Buy and raises the price target from $41 to $44.
11-05 19:02
